HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF- α) agents for rheumatic and dermatologic conditions: A systematic review and meta-analysis

International Journal of Rheumatology

Volumn 2014, Issue , 2014, Pages

  Cantini, Fabrizio ^a   Boccia, Stefania ^b   Goletti, Delia ^c   Iannone, Florenzo ^d   Leoncini, Emanuele ^b   Panic, Nikola ^b   Prignano, Francesca ^e   Gaeta, Giovanni Battista ^f  

^a MISERICORDIA E DOLCE HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIVIRUS AGENT; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PREVALENCE; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN DISEASE; SYSTEMATIC REVIEW; VIRUS REACTIVATION;

EID: 84904598299     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2014/926836     Document Type: Review

References (37)

1. Bernatsky S., Habel Y., Rahme E., Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. Journal of Rheumatology 2010 37 5 928 931 10.3899/jrheum.091107 2-s2.0-77951770108
2. Galloway J. B., Hyrich K. L., Mercer L. K., Dixon W. G., Fu B., Ustianowski A. P., Watson K. D., Lunt M., Symmons D. P. M., Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011 50 1 124 131 10.1093/rheumatology/keq242 2-s2.0-79951712039
3. Wong G. H. W., Goeddel D. V., Tumor necrosis factors α and β inhibit virus replication and synergize with interferons. Nature 1986 323 6091 819 822 10.1038/323819a0 2-s2.0-0022929999 (Pubitemid 17176583)
4. Mestan J., Digel W., Mittnacht S., Hillen H., Blohm D., Möller A., Jacobsen H., Kirchner H., Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 1986 323 6091 816 819 10.1038/323816a0 2-s2.0-0023035026 (Pubitemid 17168636)
5. Ganem D., Prince A. M., Hepatitis B virus infection-natural history and clinical consequences. The New England Journal of Medicine 2004 350 11 1118 1129 10.1056/NEJMra031087 2-s2.0-1542316127 (Pubitemid 38298992)
6. Guidotti L. G., Ando K., Hobbs M. V., Ishikawa T., Runkel L., Schreiberu R. D., Chisari F. V., Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 3764 3768 10.1073/pnas.91.9.3764 2-s2.0-0028348561 (Pubitemid 24139512)
7. Guidotti L. G., Ishikawa T., Hobbs M. V., Matzke B., Schreiber R., Chisari F. V., Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996 4 1 25 36 10.1016/S1074-7613(00)80295-2 2-s2.0-0030021968 (Pubitemid 26054933)
8. WHO, Hepatitis B. Fact Sheet 2014 204. http://www.who.int/mediacentre/ factsheets/fs204/en/index.html
9. Raimondo G., Pollicino T., Cacciola I., Squadrito G., Occult hepatitis B virus infection. Journal of Hepatology 2007 46 1 160 170 10.1016/j.jhep.2006.10. 007 2-s2.0-34047189890 (Pubitemid 44827430)
10. Pérez-Alvarez R., Díaz-Lagares C., García- Hernández F., Lopez-Roses L., Brito-Zerón P., Pérez-De-Lis M., Retamozo S., Bové A., Bosch X., Sanchez-Tapias J., Forns X., Ramos-Casals M., Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011 90 6 359 371 10.1097/MD.0b013e3182380a76 2-s2.0-80755140623
11. Caporali R., Bobbio-Pallavicini F., Atzeni F., Sakellariou G., Caprioli M., Montecucco C., Sarzi-Puttini P., Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care and Research 2010 62 6 749 754 10.1002/acr.20130 2-s2.0-77953102456
12. Cassano N., Mastrandrea V., Principi M., Loconsole F., De Tullio N., Di Leo A., Vena G. A., Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. Journal of Biological Regulators and Homeostatic Agents 2011 25 2 285 289 2-s2.0-80052896047
13. Charpin C., Guis S., Colson P., Borentain P., Mattéi J., Alcaraz P., Balandraud N., Thomachot B., Roudier J., Gérolami R., Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Research and Therapy 2009 11 6, article R179 10.1186/ar2868 2-s2.0-77952468463
14. Kim Y. J., Bae S.-C., Sung Y.-K., Kim T.-H., Jun J.-B., Yoo D.-H., Kim T. Y., Sohn J. H., Lee H.-S., Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor- α blocker in the treatment of rheumatic diseases. The Journal of Rheumatology 2010 37 2 346 350 10.3899/jrheum.090436 2-s2.0-76649143366
15. Lan J., Chen Y., Hsieh T., Chen Y., Hsieh C., Chen D., Yang S., Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Annals of the Rheumatic Diseases 2011 70 10 1719 1725 10.1136/ard.2010.148783 2-s2.0-80052514253
16. Mori S., Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Modern Rheumatology 2011 21 6 621 627 10.1007/s10165-011- 0458-z 2-s2.0-84855667800
17. Ryu H. H., Lee E. Y., Shin K., Choi I. A., Lee Y. J., Yoo B., Park M., Park Y., Bae S., Yoo W. H., Kim S. I., Lee E. B., Song Y. W., Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF α agents: a retrospective analysis of 49 cases. Clinical Rheumatology 2012 31 6 931 936 10.1007/s10067-012-1960-1 2-s2.0-84863716498
18. Tamori A., Koike T., Goto H., Wakitani S., Tada M., Morikawa H., Enomoto M., Inaba M., Nakatani T., Hino M., Kawada N., Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. Journal of Gastroenterology 2011 46 4 556 564 10.1007/s00535-010-0367-5 2-s2.0-79959848770
19. Urata Y., Uesato R., Tanaka D., Kowatari K., Nitobe T., Nakamura Y., Motomura S., Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Modern Rheumatology 2011 21 1 16 23 10.1007/s10165-010-0337-z 2-s2.0-79951952735
20. Vassilopoulos D., Apostolopoulou A., Hadziyannis E., Papatheodoridis G. V., Manolakopoulos S., Koskinas J., Manesis E. K., Archimandritis A. I., Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Annals of the Rheumatic Diseases 2010 69 7 1352 1355 10.1136/ard.2009.127233 2-s2.0-77954991111
21. Liberati A., Altman D. G., Tetzlaff J., Mulrow C., Gøtzsche P. C., Ioannidis J. P. A., Clarke M., Devereaux P. J., Kleijnen J., Moher D., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Italian Journal of Public Health 2009 6 4 354 391 2-s2.0-76549089252
22. Stuart A., Ord J. K., Arnold S. F., O'Hagan A., Kendall M. G., Kendall's Advanced Theory of Statistics 1994 6th London, UK Edward Arnold
23. DerSimonian R., Laird N., Meta-analysis in clinical trials. Controlled Clinical Trials 1986 7 3 177 188 10.1016/0197-2456(86)90046-2 2-s2.0-0022992740 (Pubitemid 17189972)
24. Higgins J. P. T., Thompson S. G., Deeks J. J., Altman D. G., Measuring inconsistency in meta-analyses. British Medical Journal 2003 327 7414 557 560 10.1136/bmj.327.7414.557 2-s2.0-0041876133 (Pubitemid 37088507)
25. Higgins J. P. T., Thompson S. G., Spiegelhalter D. J., A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society A: Statistics in Society 2009 172 1 137 159 10.1111/j.1467-985X.2008.00552.x MR2655609 2-s2.0-57849168342
26. Roux C. H., Brocq O., Breuil V., Albert C., Euller-Ziegler L., Safety of anti-TNF- α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006 45 10 1294 1297 10.1093/rheumatology/kel123 2-s2.0-33749587637 (Pubitemid 44542073)
27. Zingarelli S., Airò P., Frassi M., Bazzani C., Scarsi M., Puoti M., Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo 2008 60 1 22 27 2-s2.0-57149139723
28. Chung S. J., Kim J. K., Park M. C., Park Y. B., Lee. S. K., Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. Journal of Rheumatology 2009 36 11 2416 2420 10.3899/jrheum.081324
29. Fotiadou C., Lazaridou E., Ioannides D., Safety of anti-tumour necrosis factor- α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. Journal of the European Academy of Dermatology and Venereology 2011 25 4 471 474 10.1111/j.1468-3083.2010.03754.x 2-s2.0-79952412110
30. Prignano F., Ricceri F., Pescitelli L., Zanieri F., Lotti T., Tumour necrosis factor- α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. British Journal of Dermatology 2011 164 3 645 647 10.1111/j.1365-2133.2010.10140.x 2-s2.0-79952367859
31. Kato M., Atsumi T., Kurita T., Odani T., Fujieda Y., Otomo K., Horita T., Yasuda S., Koike T., Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases. The Journal of Rheumatology 2011 38 10 2209 2214 10.3899/jrheum.110289 2-s2.0-80053483118
32. Cho Y.-T., Chen C.-H., Chiu H.-Y., Tsai T.-F., Use of anti-tumor necrosis factor- α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. Journal of Dermatology 2012 39 3 269 273 10.1111/j.1346-8138.2011.01434.x 2-s2.0-84857657384
33. Giardina A. R., Ferraro D., Ciccia F., Ferrante A., Di Stefano R., Craxì A., Triolo G., No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. Clinical and Experimental Rheumatology 2013 31 1 25 30 2-s2.0-84874839170
34. Laurenti R., Giovannangeli F., Gubinelli E., Viviano M. T., Errico A., Leoni L., Ballanti E., Migliore A., Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clinical and Developmental Immunology 2013 2013 5 410521 10.1155/2013/410521 2-s2.0-84876555835
35. Navarro R., Vilarrasa E., Herranz P., Puig L., Bordas X., Carrascosa J. M., Taberner R., Ferrán M., García-Bustinduy M., Romero-Maté A., Pedragosa R., García-Diez A., Daudén E., Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. The British Journal of Dermatology 2013 168 3 609 616 10.1111/bjd.12045 2-s2.0-84882249101
36. Nishida T., Hiramatsu N., Mizuki M., Nagatomo I., Kida H., Tazumi K., Shinzaki S., Miyazaki M., Yakushijin T., Tatsumi T., Iijima H., Kiso S., Kanto T., Tsujii M., Takehara T., Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic. Hepatology Research 2013 43 4 339 346 10.1111/j.1872-034X.2012.01073.x 2-s2.0-84871752851
37. Stasi R., Sarpatwari A., Segal J. B., Osborn J., Evangelista M. L., Cooper N., Provan D., Newland A., Amadori S., Bussel J. B., Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009 113 6 1231 1240 10.1182/blood-2008-07-167155 2-s2.0-60849086771